Five-year survival outcomes from CRES 3 T: S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.

• DOI: 10.1200/jco.2025.43.16_suppl.8064
• Publication Date: 2025-05-28T13:33:39Z
• Authors: Kazuya Takamochi; Kenji Suzuki; Morihito Okada; Seiji Niho; Satoshi Ishikura; Shunsuke Oyamada; Takuhiro Yamaguchi; Hirotoshi Horio; Norihiko Ikeda; Fumihiro Tanaka; Satoshi Shiono; Tomohiro Haruki; Hidemi Suzuki; Hiroyuki Ito; Hidetaka Uramoto; Norihito Okumura; Masahiro Tsuboi

8064 Background: CRES 3 T is a multicenter, single-arm, confirmatory trial of S-1 plus cisplatin and concurrent radical-dose thoracic radiotherapy (TRT) followed by surgery in patients with superior sulcus tumor (SST). The 3-year overall survival (OS) progression-free (PFS) rates were 73% (95% confidence interval [CI]; 60–83%) 53% CI; 40–65%), respectively. primary endpoint, OS rate, was met. We report the exploratory analyses outcomes approximately 5 years after last patient enrolled. Methods: Patients SST (pathologically proven non-small cell lung cancer that directly invades chest wall, including first rib or further cephalad, subclavian artery, vein according to computed tomography magnetic resonance imaging) received induction therapy comprising three cycles TRT (66 Gy 33 fractions) surgery. administered orally at 40 mg/m 2 twice daily for 14 days along an intravenous infusion (60 ) on day 1. treatment repeated every four weeks. 5-year OS, PFS, patterns postoperative recurrence analyzed. Prognostic factors analyzed who underwent surgical resection using Cox proportional hazard model. Results: median follow-up duration 60 eligible 67.1 months. PFS 66.3% 52.8–76.8) 48.1% CI: 35.0–60.0), 49 71.0 71.0% 56.0–81.7) 52.8% 37.9–65.6), Age only significant prognostic factor ( P = 0.01, HR 1.1, 95% 1.02–1.20). Sex, smoking status, clinical stage, N stage (cN0 versus cN1/ipsilateral supraclavicular cN3), symptoms associated brachial plexus involvement, histology, preoperative serum CEA CYFRA levels, pathological complete response, major response had no impacts OS. Twenty (41%) developed relapse. relapse locoregional one (2%), distant metastasis 16 (33%), both (6%) patients. Conclusions: Better compared those pivotal studies (5-year OS: 56% JCOG9806 44% SWOG9416/INT0160) indicated could be new standard SST. Clinical information: s031180401 .